In swine and poultry feed milling operations, chlortetracycline premix veterinary grade API is typically received as a 10.0% or 20.0% chlortetracycline hydrochloride medicated article deposited onto a calcium carbonate, rice hull, or corn cob carrier, and the first critical unit operation is controlled stepwise dilution rather than direct addition to the main mixer. Under FDA 21 CFR 558.128, the API is incorporated into a Type A medicated article that is subsequently distributed through Type B and Type C medicated feed intermediates; a facility operating under 21 CFR 225 is required to maintain master records, batch production records, and validated flush or sequencing procedures for carryover control. The main ribbon mixer or twin-shaft paddle mixer is generally charged with the carrier portion, followed by the CTC premix, and blended for a site-qualified interval; homogeneity is confirmed by stratified sampling according to ISO 6497 and assayed using a stability-indicating HPLC or microbiological plate assay, with acceptance criteria commonly set at a coefficient of variation not exceeding 5.0% across all sampling points. If the premix is added directly onto a fast-moving auger or into a pre-mixed feed without a 1:10 or 1:20 intermediate dilution, the risk of active segregation increases because the API-loaded carrier particles are denser than many fibrous feed components; electrostatic adhesion also rises when ambient relative humidity falls below 40%. The final medicated complete feed, mineral supplement, or free-choice loose feed is then pelleted or extruded only after conditioning temperatures and die retention times are evaluated against tetracycline thermal degradation; pellet mills operating above 85°C can initiate epimerization and reduce residual active titre. Batch records must document final feed concentration, target species, withdrawal period, and any sequencing flush, because carryover into non-medicated feed is a regulatory non-compliance rather than a cosmetic defect.

The principal processing conflict in medicated feed production is the thermal window of pellet conditioning; chlortetracycline hydrochloride tolerates short exposure to conditioning steam only when the conditioner temperature is held within a species-specific validated range, and die-generated frictional heat in large-diameter pellet mills can drive local temperatures far above the set point. Production lines with long retention conditioners or expanders above 80°C therefore require post-pellet liquid application of the medicated article or a switch to crumble manufacture, because the residual potency loss across the pellet die is not linear and cannot be corrected by simple overage. Carryover control is validated through a sequencing study in which a non-medicated flush batch is run after the highest-strength medicated batch, and the assay result in the flush is compared against the carryover limit established in the site's 21 CFR 225 programme; facilities without a dedicated flush cycle or sufficient line cleaning frequently record carryover into non-medicated feeds at levels that exceed the detection limit and trigger a regulatory action. The finished medicated article is sampled at the points of greatest segregation risk—mixer discharge, bucket elevator drop points, and pellet cooler discharge—because post-mix handling can undo a satisfactory mixer CV within minutes. Terminal finished products include loose feed, pellets, crumbles, and mineral supplements, each with a different segregation and moisture profile; the batch production record therefore records not only the quantity of API but also the mechanical path through the mill.

How Does pH and Water Hardness Limit the Viable Holding Time of Soluble Powders?

A water-soluble oral powder containing chlortetracycline hydrochloride is rarely a simple dry blend of API and dextrose because the reconstituted drinking water environment controls whether the tetracycline nucleus remains intact or converts to 4-epichlortetracycline via reversible epimerization under neutral-to-alkaline pH. Formulators therefore co-dry or dry-blend the API with a citrate buffer, such as citric acid and sodium citrate, at a ratio that brings the final solution pH into the acidic range below 6.0, and the manufacturing process is carried out at a product-moisture limit below 1.5% to prevent premature hydrolysis in the finished sachet or pail. In poultry and swine barns, the powder is reconstituted in a stock tank and dispensed through an in-line proportioner at a calibrated 1:128 or 1:256 dilution; the proportioner is validated by chloride-ion or dye tracer because variations in stock concentration directly alter the delivered mg/kg body-weight dose. Water hardness causes a separate compatibility constraint: divalent calcium and magnesium ions form poorly absorbable tetracycline chelates and may produce turbidity; the powdered formulation is therefore restricted to softened or conditioned water, and the label must state that high-hardness water, iron-containing well water, and alkaline carbonate buffers are incompatible. Once reconstituted, the solution is not a pharmaceutically stable presentation; a maximum use period of 24 h is a practical boundary in most field protocols, and tanks must be cleaned daily because residual organic matter accelerates microbial growth and antibiotic degradation. The dry powder itself is filled into polyethylene or foil-laminated sachets under relative humidity not exceeding 35%, and the final product is tested by microbiological assay per Ph. Eur. 2.7.2 or USP <81> with a potency specification tied to the registered label claim.

The dry-mix manufacturing process for water-soluble powder has a separate constraint: acidic buffer salts such as citric acid are hygroscopic and can melt or clump in high-humidity regions, so the blending suite is conditioned at ≤35% RH and the powder is filled into foil-laminated sachets immediately after blending. Ph. Eur. 2.7.2 or a validated HPLC method is used for release, and dissolution rate in water at 20–25°C is checked to ensure that the powder passes through a 250 µm sieve and does not form floating agglomerates in the stock tank. Because the product is administered through nipple drinkers or bell drinkers in large poultry houses, residue formation in water lines is a practical concern; the acidic formulation reduces scale build-up but may corrode galvanised fittings if the stock solution is overdosed, so the label directs a final water pH check and flushing of lines after the medication period. The final product is categorised as an oral solution/powder presentation, and the prepared medicated water must be protected from direct sunlight because ultraviolet exposure accelerates photo-degradation of the tetracycline ring.

Compression Physics and Cation-Mediated Degradation in Tablet Cores

Veterinary tablet formulations containing chlortetracycline hydrochloride encounter two simultaneous process constraints: the crystalline API has poor compactability and flow, and the tetracycline moiety is incompatible with di- and tri-valent metal ion excipients used in standard tableting. Direct compression is possible only when the active load is low; at higher potencies, a wet granulation step using a 5% povidone K30 hydroalcoholic solution is preferred, followed by fluid-bed drying at an inlet temperature no greater than 60°C and a product temperature kept at or below 45°C because the hydrochloride salt is thermolabile in the presence of moisture. The dried granulate is milled to a particle-size distribution that passes through a 1.0 mm screen, then lubricated with magnesium stearate at 0.25–0.75 wt%; over-lubrication above 1.0 wt% reduces tablet tensile strength and slows dissolution, while calcium phosphate, calcium carbonate, and magnesium trisilicate are avoided entirely because they form tetracycline chelates and reduce oral bioavailability. Tablet cores are compressed on a rotary tablet press with a target hardness of 6–10 kp, and friability is controlled to less than 1.0% per USP <1216> or equivalent; disintegration is evaluated by USP <701> and dissolution by USP <711> using an acidic media matrix because the API exhibits pH-dependent solubility. Finished tablets are protected from light and humidity by aluminium/PVC blister packaging, and stability batches are stored under 25°C/60% RH and 40°C/75% RH conditions according to the applicable veterinary stability protocol. The end product is used in companion animals and pre-ruminant calves, but prescribers must account for food intake and divalent-cation-rich diets, because milk replacer containing high calcium can reduce the effective absorbed dose.

The dissolution test for chlortetracycline hydrochloride tablets is pH-sensitive; a method using 0.01 M hydrochloric acid at 37°C with USP <711> apparatus II at 50 rpm is common because higher pH media can precipitate the base or form salts with phosphate or carbonate buffers. Tablet formulations are therefore benchmarked against both the release profile and the impurity profile; 4-epichlortetracycline and anhydrochlorteracycline-related substances are monitored in stability samples, and packaging is selected to reduce the headspace oxygen and moisture that accelerate degradation. Production-scale experience shows that wet granulation with sticky povidone solutions can cause wall adhesion in high-speed mixers if the binder temperature is below 20°C or if the granulation end-point is misjudged; the wet mass is therefore discharged at a predetermined ampere load on the mixer impeller rather than by time alone, and the drying curve is monitored until the loss on drying is 1.0–1.5% prior to lubrication. Residual solvents from hydroalcoholic granulation are controlled according to VICH GL18, and the release specification includes identity, assay, related substances, dissolution, and water content.

For injectable presentations, chlortetracycline hydrochloride is processed as a sterile dry-fill powder or lyophilized plug rather than a ready-to-use aqueous injection because the tetracycline ring undergoes pH-dependent epimerization in solution and the hydrochloride salt has insufficient hydrolytic stability to support terminal steam sterilisation at 121°C without significant potency loss. The manufacturing line therefore uses aseptic processing after depyrogenation of the primary packaging; glass vials are washed and dry-heat depyrogenated at 250°C for at least 30 min, while the API and cryoprotectant matrix, typically mannitol or trehalose plus a hydrochloric acid/sodium hydroxide buffer targeting a pH below 3.5, are dissolved in Water for Injections and sterilised by passage through a 0.22 µm membrane filter. The solution is filled into vials under Grade A conditions and lyophilised with a product-temperature profile developed below the collapse temperature of the formulation; published data for this specific chlortetracycline configuration are limited, so cycle development must rely on freeze-drying microscopy and differential scanning calorimetry. After lyophilisation, residual moisture is controlled below 2.0%, and the product is tested for bacterial endotoxins per USP <85>, particulate matter per USP <788>, sterility per USP <71>, and assay per USP <81> or a validated HPLC method. The reconstituted injection is intended for deep intramuscular use in large animals; it must not be administered intravenously or mixed with alkaline solutions, and reuse of the reconstituted vial after 6 h is generally contraindicated unless a preservative system has been specifically validated. Withdrawal periods and edible-tissue residue limits are jurisdiction-specific and must be derived from residue depletion studies in the target species rather than extrapolated from other tetracycline salts.

Lyophilisation development for this API is constrained by the glass-transition and collapse temperature of the acidified formulation, which is depressed by the hydrochloride salt and any residual organic co-solvent; a conservative cycle uses a shelf temperature of −30°C for primary drying and a final secondary drying temperature not exceeding 25°C until the moisture specification is met. The filling line uses weight-check stations and periodic in-process sterility testing, and the stoppers are selected for low moisture vapour transmission because a poorly seated lyophilisation stopper can raise headspace moisture and reduce reconstituted product clarity. The reconstituted solution must be inspected for particulate matter before injection; visible precipitates may form if the diluent contains calcium or if the vial is mixed with a sodium bicarbonate solution, and such admixtures are contraindicated because the pH shift converts the hydrochloride to the poorly soluble free base. The final product is used in deep intramuscular sites in cattle and swine under veterinary supervision, but the injection site reaction and the long withdrawal period must be evaluated by residue studies under the applicable national registration.

When Low-Dose Capsule Blends Require Segregation and Electrostatic Control

Capsule filling of low-dose chlortetracycline hydrochloride blends is governed by the electrostatic behaviour of the API, which is exacerbated by the low relative humidity common in dry powder handling suites; the API tends to adhere to stainless steel contact surfaces and to gelatin or hydroxypropyl methylcellulose capsule shells, causing weight variation that cannot be corrected by increasing fill weight alone. A pre-blend is prepared by trituration of the API with a compatible diluent such as lactose monohydrate or pregelatinised maize starch, and a glidant such as colloidal anhydrous silica is added at 0.2–0.5 wt%; the pre-blend is passed through a 500 µm screen and re-blended before filling on a tamping-pin capsule machine or a dosator-type capsule machine, with pin settings adjusted so that plug hardness remains within a validated ejection-force window. The process area humidity is maintained between 40% and 50% RH, because lower humidity increases static charging and higher humidity promotes hydrolysis of the tetracycline ring in the open powder bed. Fill weight and content uniformity are checked according to USP <905>, and capsules are packaged in moisture-protective blisters with desiccant where the capsule shell material has a higher moisture vapour transmission rate than the API granulate can tolerate. The final capsule presentation, typically in #3 to #0 shells for companion animals, must not be combined with iron supplements or multivalent antacids during dosing because simultaneous administration can reduce absorption; the capsule formulation itself excludes croscarmellose sodium at high alkalinity and other effervescent or carbonate-based disintegrants that create micro-pH conditions outside the stable acidic range.

The capsule process may be preceded by slugging or roller compaction only when the pre-blend density is too low for consistent volumetric filling; roller compaction with a 1.0 mm screen and a roll pressure of 30–50 bar can improve bulk density, but the compaction step must be kept below the point at which the API is mechanically amorphised, because amorphous chlortetracycline hydrochloride is more hygroscopic and chemically unstable. Capsule shell selection also affects stability: hard gelatin capsules with a moisture content of 13–15% can transfer water to a low-moisture granulate, while HPMC capsules with lower equilibrium moisture may be preferred for moisture-sensitive tetracycline formulations. The final blend is tested for bulk density, tapped density, Hausner ratio, and flow through an orifice, with a Hausner ratio below 1.25 or a Carr index below 25% indicating acceptable flow for high-speed filling. Content uniformity samples are taken at beginning, middle, and end of the filling run, and the acceptance value is calculated according to USP <905>; if the acceptance value exceeds the compendial limit, the batch is not re-blended without a full deviation investigation because re-blending may reduce particle size and worsen segregation.

During re-granulation of a chlortetracycline premix into a low-dust oral granule for calves, piglets, or small ruminants, the process objective shifts from simple dilution to controlled agglomeration around the loaded carrier so that the finished granule disperses uniformly over feed or in an oral drench rather than segregating in the bucket. A fluid-bed top-spray granulator is charged with the premix and a compatible carrier, and an aqueous binder such as hydroxypropyl methylcellulose or povidone at 3–5% solids is sprayed at an inlet temperature of 55–65°C and an atomisation pressure of 1.5–2.0 bar; the product temperature is maintained below 45°C, and final granule moisture is dried to 2.0% or lower before discharge. The dried granules are sieved to a target cut of 200–800 µm, with oversized granules milled gently and undersized fines recycled into the next granulation batch; excessive fines below 100 µm raise dust and reduce dose uniformity in field top-dressing applications. Granule potency is verified by extracting a stratified sample and analysing by the same validated HPLC or microbiological assay applied to the starting premix, and the packaging is selected to prevent moisture ingress because the agglomerated product retains hygroscopic binder residues that can soften and cake in high-humidity barns. For oral drench solutions prepared from the same API, the compounding step uses a citrate-acidified vehicle to hold the pH below 5.0 and the solution is used immediately; compounding in alkaline or unbuffered vehicles is contraindicated, and published data for extended stability of this non-licensed presentation are limited. The terminal use in the field is therefore either as a top-dress granule mixed into a small portion of the daily ration or as a freshly prepared drench, with the dose calculated on a mg/kg body-weight basis and the withdrawal period taken from the approved label for the target species.

The granulation process must be distinguished from simple premix dilution because the binder addition rate changes both granule density and active distribution; if the spray rate is too high, the bed defluidises and produces coarse over-wetted agglomerates that screen poorly and exhibit non-uniform potency. The end granules are tested for particle-size distribution by analytical sieving, bulk density, and potency in the 200–800 µm fraction, because coarse granules may be sorted out by the animal and fine granules may remain as dust in the feed bucket. For oral drench solutions, the API is dissolved in a glycerol or propylene glycol vehicle after pH adjustment, and high-shear mixing should be avoided because air entrainment in the viscous vehicle accelerates oxidative degradation; a nitrogen blanket during filling of bulk drench containers is used where the registration stability data demonstrates oxygen sensitivity. The final field product is a low-dust granule or a short-use oral solution, and the batch record cross-references the starting premix lot to maintain traceability through the feed chain.